Publications
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn’s Disease
Citation
Lefevre PLC, Dulai PS, Wang Z, Guizzetti L, Feagan BG, Pop A, Yassine M, Shackelton LM, Jairath V, Sandborn WJ, Vande Casteele N. A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. BioDrugs. 2022 Jan;36(1):85-93. doi: 10.1007/s40259-021-00512-8. Epub 2021 Dec 24. PMID: 34951696.
Abstract
Background: Certolizumab pegol (CZP) is effective for moderately to severely active Crohn’s disease (CD). Higher plasma concentrations are associated with better outcomes and increased drug clearance is the driver of subtherapeutic CZP concentrations.
